Stockscreener 앱 받기
2.98
10.51%
-0.35
시간 외 거래:
2.98
전일 마감가:
$3.33
열려 있는:
$3.13
하루 거래량:
90,730
Relative Volume:
0.44
시가총액:
$6.62M
수익:
$895.50K
순이익/손실:
$-26.30M
주가수익비율:
-1.8171
EPS:
-1.64
순현금흐름:
$-23.84M
1주 성능:
-16.76%
1개월 성능:
-39.80%
6개월 성능:
-69.20%
1년 성능:
-93.10%
1일 변동 폭
$2.65
$3.13
1주일 범위
$2.65
$3.64
52주 변동 폭
$2.65
$45.20
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
2.98 | 6.62M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
437.91 | 165.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
181.77 | 130.05B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
393.73 | 31.91B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
103.00 | 29.38B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
154.73 | 27.28B | 15.41B | 1.37B | 2.11B | 7.50 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | Maxim Group | Buy |
| 2024-11-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | 개시 | H.C. Wainwright | Buy |
Mainz Biomed N V 주식(MYNZ)의 최신 뉴스
Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Benzinga
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ) - Defense World
Mainz Biomed (MYNZ) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Mainz Biomed begins pivotal colorectal cancer test study By Investing.com - Investing.com Canada
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq
Mainz Biomed begins pivotal colorectal cancer test study - Investing.com
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan
(MYNZ) Proactive Strategies - Stock Traders Daily
Mainz Biomed secures license for pancreatic cancer test By Investing.com - Investing.com Australia
Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq
Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer - Marketscreener.com
Mainz Biomed’s Breakthrough in Pancreatic Cancer Detection - TipRanks
Mainz Biomed secures license for pancreatic cancer test - Investing.com India
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - The Manila Times
Mainz Biomed Signs Exclusive Licensing Agreement with Liquid Biosciences for Novel mRNA Biomarkers in Pancreatic Cancer Detection - Nasdaq
Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood ... - The Bakersfield Californian
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
(MYNZ) Trading Advice - Stock Traders Daily
Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire
Mainz Biomed Partners with labor team w ag to Launch ColoAlert® Colorectal Cancer Screening Test in Switzerland - Nasdaq
First DNA-Based Cancer Test Enters Swiss Market: Can Mainz Biomed Transform Screening? - StockTitan
Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group - Defense World
Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
How To Trade (MYNZ) - Stock Traders Daily
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire
Mainz Biomed Collaborates with GANZIMMUN Diagnostics to Launch Enhanced ColoAlert Colorectal Cancer Screening Test in Germany - Nasdaq
Mainz Biomed's Revolutionary DNA Tech Powers New German Cancer ScreeningWhat Sets It Apart - StockTitan
A stock that deserves closer examination: Mainz Biomed N.V (MYNZ) - US Post News
The Future of Mainz Biomed N.V: Analyzing MYNZ - The InvestChronicle
Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Canada
Mainz Biomed regains Nasdaq compliance with equity rule - MSN
Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire
Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan
Mainz Biomed Regains Compliance With Nasdaq Listing Rules - Nasdaq
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed Moves Forward With Pivotal CRC Study After Feasibility Trial - Nasdaq
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mainz Biomed N V (MYNZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.49%
자본화:
|
볼륨(24시간):